Literature DB >> 758657

Pharmacologic enhancement of gallium-67 tumor-to-blood ratios for EMT-6 sarcoma (BALB/c mice).

S M Larson, J S Rasey, Z Grunbaum, D R Allen.   

Abstract

At various intervals after intravenous injection of carrier-free 67Ga-citrate, iron dextrane or deferoxamine mesylate was injected into EMT-6 tumor-bearing BALB/c mice. After treatment, rapid clearance of 67Ga from soft tissues was observed. Tumor uptake was not greatly affected, and so increased tumor-to-blood ratios were observed. The authors conclude that these drugs can enhance target-to-nontarget uptake ratios for tumors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 758657     DOI: 10.1148/130.1.241

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.

Authors:  K Koizumi; N Tonami; K Hisada
Journal:  Eur J Nucl Med       Date:  1982

2.  Tomographic gallium-67 citrate scanning. Useful new surveillance for metastatic melanoma.

Authors:  J M Kirkwood; J E Myers; D R Vlock; R Neumann; S Ariyan; A Gottschalk; P Hoffer
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

3.  Gallium-67 scintigraphy in patients with hemochromatosis treated by deferoxamine.

Authors:  S Nagamachi; H Hoshi; S Jinnouchi; S Ono; K Watanabe
Journal:  Ann Nucl Med       Date:  1988-05       Impact factor: 2.668

4.  Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.

Authors:  C Motta-Hennessy; S A Eccles; C Dean; G Coghlan
Journal:  Eur J Nucl Med       Date:  1985
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.